Dr. Joel S. Hayflick

powered by
COS Expertise®
Genentech, Inc.
Oncology Early Development
Medical Affairs
Senior Early Development Team Leader
Professional Headshot of Joel S. Hayflick

Mailing Address

Genentech, Inc.
1 DNA Way
South San Francisco, California 94080-4990
United States

Contact Information

joel_hayflick@yahoo.com

Qualifications

Ph.D., Oregon Health & Science University, Cell Biology and Anatomy, 1992.
B.A., Stanford University, 1979.

Previous Positions

1998-2006, Principal Scientist, ICOS Corporation, Discovery Biology
1995-1998, Senior Staff Scientist, ICOS Corporation
1992-1995, Staff Scientist, ICOS Corporation
1986-1992, Doctoral Student, Oregon Health & Science University, School of Medicine (SOM), Cell Biology and Anatomy, Vollum Institute for Advanced Biomedical Research
1980-1986, Senior Research Associate, Genentech, Inc.
1979-1980, Research Assistant, University of California, San Francisco, School of Medicine, Biochemistry and Biophysics, Howard Hughes Medical Institute

Expertise and Research Interests

Dr. Hayflick's career has focused on the biology of cellular growth control in normal and disease processes. He contributed pioneering work on the roles that growth factors and cellular adhesion play in the development of cancer and inflammation. He identified new growth factors by elucidating their primary structure, genomic organization, and biosynthetic pathways. He worked on adhesion protein and growth factor receptor biology, signal transduction pathways and the creation of drugs that modulate all of these for the treatment of human disease.

Formerly, as a member of the Research Department at ICOS Corp., his role was to direct a group of talented scientists who identified and validated new drug targets, identified small molecule and/or biological modulators of these targets through high throughput screening, and carried out IND enabling studies in preparation for clinical trials. To achieve these goals, new technologies were applied (focused on genomics, proteomics, biomarker assessment and structural bioinformatics) as well as implementation of traditional methods (medicinal chemistry, pharmacology, in vivo efficacy, and toxicology).

Future Research

Additional interests are miniaturization (nanotechnology) and its application to target discovery/validation, drug discovery and biomarker development.

High-throughput protein structure determination and its applications to functional genomics and drug discovery.

Migrating higher throughput ADME/toxicity assays into earlier stages of the lead optimization/medicinal chemistry phase of drug development as a means of increasing the likelihood of future clinical success.

Industrial Relevance

Dr. Hayflick has contributed to the development of the following marketed products: bacterial expression of recombinant human growth hormone (rhGH), bacterial expression of recombinant bovine growth hormone (rbGH) and cDNA cloning for recombinant human tissue plasminogen activator (rhTPA). Six additional products to which he has contributed expertise during discovery and development phases have been tested in human or animal clinical trials. They are cDNA cloning for recombinant human tumor necrosis factor alpha (rhTNFalpha) for cancer, in vitro biological characterization of humanized anti-CD18 monoclonal antibody for multiple sclerosis and hemorrhagic shock, target validation and preclinical efficacy studies of humanized anti-ICAM-3 monoclonal antibody for myeloid leukemia, in-licensing due diligence for resiniferatoxin (a naturally occurring, small molecule vanilloid receptor agonist) for interstitial cystitis, cDNA cloning for recombinant chicken and porcine growth hormones for agricultural use.

Dr. Hayflick was a member of the Discovery Biology Research Management Committee, a group charged with making tactical decisions. His management responsibility was for teams that have focused on discovering small molecule inhibitors of phosphatidylinositol 3-kinase delta (anti-cancer, anti-inflammatory), protein-protein interactions (viral, neuroprotective/pain and immunological targets), as well as anti-fungal and anti-bacterial research projects.

He has led company activities as part of external corporate collaborative efforts intended to develop and optimize tyrosine phosphatase inhibitors for clinical testing (Ceptyr, Inc.) and leukocyte adhesion modulators (Abbott Laboratories).

Dr. Hayflick routinely evaluates technology from research laboratories in both academic and commercial organizations. He actively participates in business to business interactions from technology evaluation through structuring of business terms and due diligence both on the in-licensing as well as the out-licensing sides.

Honors and Awards

2007, Invited Speaker, Keystone Symposium: PI3-Kinase Signalling and Disease, Santa Fe, NM USA, P110 delta as a target for inflammatory disease
2006, Invited Speaker, Biochemical Society Focused Meeting: 2nd PI3-Kinase Signalling and Disease Meeting, Bath, UK, PI3-Kinase Delta Signaling in Pathobiology
2005, Invited Speaker, GTCbio Conferences, 2nd Cancer Drug Research and Development Meeting, Philadelphia, PA USA, Small molecule inhibitors of phosphatidylinositol 3-kinase (PI3-K) delta for the treatment of cancer
2005, Invited Speaker, Keystone Symposium: Meeting the Challenges of Drug Discovery, Vancouver, BC Canada,, PI3 Kinase Delta Inhibitors for the Treatment of Cancer and Autoimmune Disease
2003, Invited Speaker, Biochemical Society Focused Meeting: PI3-Kinase Signalling and Disease, Novartis, Horsham, UK, Role of PI3-K P110 Delta in Leukocyte Function
2002, Invited Speaker, Biochemical Society Focused Meeting: PI3-Kinases in the Immune System, Novartis, Horsham UK, A role for PI3-K in Neutrophil Function
1999, Invited Speaker, Program in Immunology-Annual Departmental Retreat, University of Calgary, Lectomedin-1: Cloning, Distribution and Suggested Functions
1997, Invited Speaker, Keystone Symposium: T Cell Activation, ICAM-3 and T Cell Signalling
1997, Invited Speaker, Nora Eccles Harrison Cardiovascular Research and Training Institute, Serine Phosphorylation of the Cytoplasmic Region of ICAM-3 Contributes to Outside-In Signalling
1993, Invited Speaker, Inflammatory Renal Disease Symposium, Wellcome Trust, Royal College of Physicians, ICAM-3 and Lymphocyte Activation in Renal Disease
1990-1991, N.L. Tartar Graduate Fellowship, Oregon Medical Research Foundation, Oregon Health Sciences University, Cellular Biology
1987-1988, N. L. Tartar Graduate Fellowship, Oregon Medical Research Foundation, Oregon Health Sciences University, Cellular Biology
1985, Performance Award, Genentech, Inc.
1982, Performance Award, Genentech, Inc.

Memberships

American Association for Cancer Research
American Association for the Advancement of Science
American Chemical Society
American Society for Cell Biology
Inflammation Research Association
Society for Experimental Biology and Medicine

Patents

Phosphoinositide 3-Kinase Inhibitors for Inhibiting Leukocyte Accumulation, Patent Number: 20080287469, 2008, Industry, United States of America.
Methods of inhibiting angiogenesis, Patent Number: 20060079538, 2006, Industry, United States of America.
Methods of inhibiting leukocyte accumulation, Patent Number: WO 2006/089106, 2006, Industry, United Kingdom.
Methods for treating and/or preventing aberrant proliferation of hematopoietic cells, Patent Number: 20060106038, 2006, Industry, United States of America.
Methods of inhibiting immune responses stimulated by an endogenous factor, Patent Number: WO 2005/016348, 2005, Industry, United Kingdom.
Methods of inhibiting leukocyte accumulation, Patent Number: WO 2005/016349, 2005, Industry, United Kingdom.
Methods of inhibiting immune responses stimulated by an endogenous factor, Patent Number: 20050043239, 2005, Industry, United States of America.
Methods of inhibiting leukocyte accumulation, Patent Number: 20050054614, 2005, Industry, United States of America.
Agents that disrupt PSD95 - nNOS interaction, compositions containing the same, and therapeutic uses thereof, Patent Number: WO 2005/097090, 2005, Industry, United Kingdom.
Methods for treating mast cell disorders, Patent Number: WO 2005/120511, 2005, Industry, United Kingdom.
Phosphoinositide 3-kinase delta selective inhibitors for inhibiting angiogenesis, Patent Number: WO 2005/112935, 2005, Industry, United Kingdom.
Methods for treating and/or preventing aberrant proliferation of hematopoietic cells, Patent Number: WO 2005/117889, 2005, Industry, United Kingdom.
Methods for treating mast cell disorders, Patent Number: CA2569406, 2005, Industry, Canada.
Lectomedin materials and methods, Patent Number: US6479256, 2002, Industry-owned, United States of America.
Methods and reagents for inhibiting furin endoprotease, Patent Number: US6022855, 2000, Institution-owned, United States of America.
Lectomedin materials and methods, Patent Number: US19990262537, 2000, Industry, United States of America.
Lectomedin materials and methods, Patent Number: WO 2000/052039, 2000, Industry, United Kingdom.
Lectomedin materials and methods, Patent Number: CA2322731, 1999, Industry, Canada.
Lectomedin materials and methods, Patent Number: WO 1999/045111, 1999, Industry, United Kingdom.
Methods and reagents for inhibiting furin endoprotease, Patent Number: US5604201, 1997, Institution-owned, United States of America.
Methods and reagents for inhibiting furin endoprotease, Patent Number: WO 1994/016073, 1994, Institution, United Kingdom.

Publications

  • Florio S, Loh C, Huang AE, Iwamaye AE, Kitto KF, Fowler KW, Treiberg JA, Hayflick JS, Fairbanks CA, Walker JM, Lai Y (2009) Disruption of nNOS-PSD95 protein-protein interaction inhibits acute thermal hyperalgesia and chronic mechanical allodynia in rodents, British Journal of Pharmacology, 158 (2), 494-506
  • Pinho V, de Castro Russo R, Amaral FA, de Sousa LP, Barsante MM, de Souza DG, Alves-Filho JC, Cara DC, Hayflick JS, Rommel C, Ruckle T, Rossi AG, Teixeira MM (2007) Tissue- and stimulus-dependent role of phosphatidylinositol 3-kinase isoforms for neutrophil recruitment induced by chemoattractants in vivo, Journal of Immunology, 179 (11), 7891-7898
  • Al-Alwan MM, Okkenhaug K, Vanhaesebroeck B, Hayflick JS, Marshall AJ (2007) Requirement for phosphoinositide 3-kinase p110{delta} signaling in B cell antigen receptor-mediated antigen presentation, Journal of Immunology, 178 (4), 2328-2335
  • Grabher C, Cliffe A, Miura K, Hayflick J, Pepperkok R, Rorth P, Wittbrodt J (2007) Birth and life of tissue macrophages and their migration in embryogenesis and inflammation in medaka, Journal of Leukocyte Biology, 81, 263-271
  • Ferreira AM, Isaacs H, Hayflick JS, Rogers KA, Sandig M (2006) The p110delta isoform of PI3K differentially regulates beta1 and beta2 integrin-mediated monocyte adhesion and spreading and modulates diapedesis, Microcirculation, 13 (6), 439-456
  • Lee KS, Lee HK, Hayflick JS, Lee YC, Puri KD (2006) Inhibition of phosphoinositide 3-kinase delta attenuates allergic airway inflammation and hyperresponsiveness in murine asthma model, FASEB Journal, 20 (3), 455-465
  • Sujobert P, Bardet V, Cornillet-Lefebvre P, Hayflick JS, Prie N, Verdier F, Vanhaesebroeck B, Muller O, Pesce F, Ifrah N, Hunault-Berger M, Berthou C, Villemagne B, Jourdan E, Audhuy B, Solary E, Witz B, Harousseau JL, Himberlin C, Lamy T, Lioure B, Cahn JY, Dreyfus F, Mayeux P, Lacombe C, Bouscary D, Essential Role for the P110delta Isoform in Phosphoinositide 3-kinase Activation and Cell Proliferation in Acute Myeloid Leukemia., Blood, 106(3), 1063-6, Aug 2005 Abstract
  • Puri KD, Doggett TA, Huang CY, Douangpanya J, Hayflick JS, Turner M, Penninger J, Diacovo TG (Jul 2005) The role of endothelial PI3Kgamma activity in neutrophil trafficking., Blood, 106 (1), 150-7 Abstract
  • Northcott CA, Hayflick J, Watts SW (Oct 2005) Upregulated Function of Phosphatidylinositol-3-kinase in Genetically Hypertensive Rats: a Moderator of Arterial Hypercontractility., Clinical and Experimental Pharmacology & Physiology, 32 (10), 851-8
  • Geng L, Tan J, Himmelfarb E, Schueneman A, Niermann K, Brousal J, Fu A, Cuneo K, Kesicki EA, Treiberg J, Hayflick JS, Hallahan DE, A Specific Antagonist of the P110delta Catalytic Component of Phosphatidylinositol 3'-kinase, IC486068, Enhances Radiation-induced Tumor Vascular Destruction, Cancer Research, 64(14), 4893-9, July 2004 Abstract
  • Puri KD, Doggett TA, Douangpanya J, Hou Y, Tino WT, Wilson T, Graf T, Clayton E, Turner M, Hayflick JS, Diacovo TG, Mechanisms and implications of phosphoinositide 3-kinase delta in promoting neutrophil trafficking into inflamed tissue, Blood, 103(9), 3448-56, 2004 Abstract
  • Northcott CA, Hayflick JS, Watts SW, PI3-kinase upregulation and involvement in spontaneous tone in arteries from DOCA-salt rats: is p110delta the culprit?, Hypertension, 43(4), 885-90, 2004 Abstract
  • Hayflick JS, A family of heptahelical receptors with adhesion-like domains: a marriage between two super families, Journal of Receptor and Signal Transduction Research, 20(2-3), 119-31, 2000 Abstract
  • Stucki A, Hayflick JS, Sandmaier BM, Antibody engagement of intercellular adhesion molecule 3 triggers apoptosis of normal and leukaemic myeloid marrow cells, British Journal of Haematology, 108(1), 157-66, 2000 Abstract
  • Kessel JM, Hayflick J, Weyrich AS, Hoffman PA, Gallatin M, McIntyre TM, Prescott SM, Zimmerman GA, Coengagement of ICAM-3 and Fc receptors induces chemokine secretion and spreading by myeloid leukocytes, Journal of Immunology, 160(11), 5579-87, June 1998 Abstract
  • Hayflick JS, Kilgannon P, Gallatin WM, The intercellular adhesion molecule (ICAM) family of proteins. New members and novel functions, Immunologic Research, 17(3), 313-27, 1998 Abstract
  • Hayflick JS, Stine J, Fox R, Hoekstra D, Gallatin WM, Functional mapping of the cytoplasmic region of intercellular adhesion molecule-3 reveals important roles for serine residues, Journal of Biological Chemistry, 272(35), 22207-14, August 1997 Abstract
  • Sadhu C, Lipsky B, Erickson HP, Hayflick J, Dick KO, Gallatin WM, Staunton DE, LFA-1 binding site in ICAM-3 contains a conserved motif and non-contiguous amino acids, Cell Adhesion and Communication, 2(5), 429-40, October 1994 Abstract
  • Anderson ED, Thomas L, Hayflick JS, Thomas G, Inhibition of HIV-1 gp160-dependent membrane fusion by a furin-directed alpha 1-antitrypsin variant, Journal of Biological Chemistry, 268(33), 24887-91, November 1993 Abstract
  • Bresnahan PA, Hayflick JS, Molloy S, Thomas G, Endoproteolysis of Growth Factors and Other Nonendocrine Precursor Proteins, In: Mechanisms of Intracellular Trafficking and Processing of Proproteins, (Ed.) Y. Peng Loh, Boca Raton, FL USA, CRC Press, 225-250, 1993, ISBN=0-8493-6870-7
  • Hayflick JS, Wolfgang WJ, Forte MA, Thomas G, A unique Kex2-like endoprotease from Drosophila melanogaster is expressed in the central nervous system during early embryogenesis, Journal of Neuroscience, 12(3), 705-17, March 1992 Abstract
  • Hayflick JS, Characterization of the Drosophila KLIP serine protease and its gene, Doctoral Dissertation, Oregon Health Sciences University, Portland, Oregon, 1992
  • Thomas G, Bresnahan PA, Hayflick JS, Leduc R, Thomas L, Thorne BA, The role of Kex2-like endoproteases in the processing of mammalian precursor proteins, 1991
  • Hayflick JS, Adelman JP, Seeburg PH, The complete nucleotide sequence of the human gonadotropin-releasing hormone gene, Nucleic Acids Research, 17(15), 6403-4, August 1989 Abstract
  • Bond CT, Hayflick JS, Seeburg PH, Adelman JP, The rat gonadotropin-releasing hormone: SH locus: structure and hypothalamic expression, Molecular Endocrinology, 3(8), 1257-62, August 1989 Abstract
  • Schofield PR, McFarland KC, Hayflick JS, Wilcox JN, Cho TM, Roy S, Lee NM, Loh HH, Seeburg PH, Molecular characterization of a new immunoglobulin superfamily protein with potential roles in opioid binding and cell contact, EMBO Journal, 8(2), 489-95, February 1989 Abstract
  • Gray A, Tam AW, Dull TJ, Hayflick J, Pintar J, Cavenee WK, Koufos A, Ullrich A, Tissue-specific and developmentally regulated transcription of the insulin-like growth factor 2 gene, DNA, 6(4), 283-95, August 1987 Abstract
  • Mason AJ, Hayflick JS, Zoeller RT, Young WS 3d, Phillips HS, Nikolics K, Seeburg PH, A deletion truncating the gonadotropin-releasing hormone gene is responsible for hypogonadism in the hpg mouse, Science, 234(4782), 1366-71, December 1986 Abstract
  • Colby WW, Hayflick JS, Clark SG, Levinson AD, Biochemical characterization of polypeptides encoded by mutated human Ha-ras1 genes, Molecular and Cellular Biology, 6(2), 730-4, February 1986 Abstract
  • Adelman JP, Mason AJ, Hayflick JS, Seeburg PH, Isolation of the gene and hypothalamic cDNA for the common precursor of gonadotropin-releasing hormone and prolactin release-inhibiting factor in human and rat, Proceedings of the National Academy of Sciences (USA), 83(1), 179-83, January 1986 Abstract
  • Mason AJ, Hayflick JS, Ling N, Esch F, Ueno N, Ying SY, Guillemin R, Niall H, Seeburg PH, Complementary DNA sequences of ovarian follicular fluid inhibin show precursor structure and homology with transforming growth factor-beta, Nature, 318(6047), 659-63, December 1985 Abstract
  • Pfaff SL, Zhou RP, Young JC, Hayflick J, Duesberg PH, Defining the borders of the chicken proto-fps gene, a precursor of Fujinami sarcoma virus, Virology, 146(2), 307-14, October 1985 Abstract
  • Pennica D, Hayflick JS, Bringman TS, Palladino MA, Goeddel DV, Cloning and expression in Escherichia coli of the cDNA for murine tumor necrosis factor, Proceedings of the National Academy of Sciences (USA), 82(18), 6060-4, September 1985 Abstract
  • Hayflick J, Seeburg PH, Ohlsson R, Pfeifer-Ohlsson S, Watson D, Papas T, Duesberg PH, Nucleotide sequence of two overlapping myc-related genes in avian carcinoma virus OK10 and their relation to the myc genes of other viruses and the cell, Proceedings of the National Academy of Sciences (USA), 82(9), 2718-22, May 1985 Abstract
  • Flohe L, Steffens GJ, Gunzler WA, Otting F, Heyneker HL, Holmes WE, Rey M, Seeburg PH, Hayflick JS, Vehar GA (1985) Insight Into Biosynthesis of Human Urokinase Forms, In: Progress in Fibrinolysis, (Eds. Davidson, J. F.; Donati, M. B.; Coccheri, S.)., Edinburgh, Churchill Livingstone, 213-216 pages (bookchapter)
  • Ullrich A, Coussens L, Hayflick JS, Dull T, Gray A, Tam AW, Lee J, Yarden TY, Libermann TA, Schlessinger J, Downward J, Whittle N, Waterfield M D, Seeburg PH (1985) Structure of Human Epidermal Growth Factor Receptor and Expression of Normal and Variant MRNAs in Epidermoid Carcinoma Cells, In: Cancer Cells 3/ Growth Factors and Transformation (Eds. J. Feramisco; B. Ozanne; C. Stiles), Cold Spring Harbor, New York, Cold Spring Harbor Laboratory, 1-9 pages (bookchapter)
  • Pennica D, Nedwin GE, Hayflick JS, Seeburg PH, Derynck R, Palladino MA, Kohr WJ, Aggarwal BB, Goeddel DV, Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin, Nature, 312(5996), 724-9, December 1984 Abstract
  • Ullrich A, Gray A, Wood WI, Hayflick J, Seeburg PH, Isolation of a cDNA clone coding for the gamma-subunit of mouse nerve growth factor using a high-stringency selection procedure, DNA, 3(5), 387-92, October 1984 Abstract
  • Dull TJ, Gray A, Hayflick JS, Ullrich A, Insulin-like growth factor II precursor gene organization in relation to insulin gene family, Nature, 310(5980), 777-81, August 1984 Abstract
  • Ullrich A, Coussens L, Hayflick JS, Dull TJ, Gray A, Tam AW, Lee J, Yarden Y, Libermann TA, Schlessinger J, et al, Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells, Nature, 309(5967), 418-25, May 1984 Abstract
  • Pennica D, Goeddel DV, Hayflick JS, Reich NC, Anderson CW, Levine AJ, The amino acid sequence of murine p53 determined from a c-DNA clone, Virology, 134(2), 477-82, April 1984 Abstract
  • Hui A, Hayflick J, Dinkelspiel K, de Boer HA, Mutagenesis of the three bases preceding the start codon of the beta-galactosidase mRNA and its effect on translation in Escherichia coli, EMBO Journal, 3(3), 623-9, March 1984 Abstract
  • Capon DJ, Seeburg PH, McGrath JP, Hayflick JS, Edman U, Levinson AD, Goeddel DV, Activation of Ki-ras2 gene in human colon and lung carcinomas by two different point mutations, Nature, 304(5926), 507-13, August 1983 Abstract
  • Adelman JP, Hayflick JS, Vasser M, Seeburg PH, In vitro deletional mutagenesis for bacterial production of the 20,000-dalton form of human pituitary growth hormone, DNA, 2(3), 183-93, 1983 Abstract
  • Seeburg PH, Sias S, Adelman J, de Boer HA, Hayflick J, Jhurani P, Goeddel DV, Heyneker HL, Efficient bacterial expression of bovine and porcine growth hormones, DNA, 2(1), 37-45, 1983 Abstract
  • Heyneker H, Homes W, Rey M, Pennica D, Shepard HM, Seeburg P, Hayflick J, Ward C, Vehar G, Steffans G, Guenzler W, Oetting F, Flohe L (1983) Functional expression of the human urokinase gene in Escherichia coli, Proceedings of the 4th International Symposium on Genetics of Industrial Microorganisms, Tokyo, Japan, Kodansha Ltd., 214-221 pages
  • Hitzeman RA, Hagie FE, Hayflick JS, Chen CY, Seeburg PH, Derynck R, The primary structure of the Saccharomyces cerevisiae gene for 3-phosphoglycerate kinase, Nucleic Acids Research, 10(23), 7791-808, December 1982 Abstract

Other Expertise

Continuing Education:
- "Designing Drugs with Optimal In Vivo Activity After Oral Administration" short course, R. T. Borchardt, Ph.D., K. Brouwer, Ph.D., V. Stella, Ph.D., D. Thakker, Ph.D. instructors, Bothell WA, 2005
- "Animal Handler Training: Mice and Rats", Bothell WA, 2004
- "Clinical Updates on Angiogenesis Inhibition for New Solid Tumor Targets" CME credit, University of Florida, Internet-based, 2004
- "Practical Medicinal Chemistry" short course, L. A. Mitscher, Ph.D. instructor, Bothell WA, 2001
- "Organic Chemistry of Drug Design and Drug Action," American Chemical Society short course, R. B. Silverman, Ph.D. instructor, Boston MA, 2000

Leadership/Management:
- "Leading the Business", BTS Inc., Gad Nestel, Dillon Lee & Francois Thrower, Instructors, Tiburon, CA 2009
- "Situational Leadership Training", Center for Leadership Studies, Inc., D. Holloway instructor, Bothell WA, 2005
- "Helping Others Succeed & Working With Diversity", The Washington Firm, Ltd., K. Moris instructor, Bothell WA 2005
- "Business and Technical Writing Workshop", IWCC Training in Communications, B. Lockwood instructor, Bothell WA, 2001
- "Management Development Program: Developing Self, Others & Groups More Effectively", M. Mirisola instructor, Bothell WA, 2000
- "Performance Management Workshop", Leadership Edge, Inc., Bothell WA, 1998
- "Leading in a Scientific Environment", W. Hitt instructor, Battelle, Bothell WA, 1995

Grant Review Panels:
- Career Investigator Program, Michael Smith Foundation for Health Research, 2003
- Genomics/Proteomics Applications in Heart, Lung and Blood Research, NIH-NHLBI Study Section, 2000
- Applications for Innovative Proteomics Research, Canada Foundation for Innovation, 2000

Dr. Hayflick was responsible for departmental goal setting, financial projections and budget oversight. He has sigificant line management experience.

Funding Received

  • Medical Research Foundation of Oregon: Graduate Research Stipend, Sep 1, 1989 to Aug 31, 1990.
  • Medical Research Foundation of Oregon: Graduate Research Stipend, Sep 1, 1987 to Aug 31, 1988.

Keywords

COS Keywords:

Anatomy, Apoptosis, Bioinformatics, Biomedical Research (Multidisciplinary), Cancer or Carcinogenesis, Cell Biology, Cell Interactions, Cellular Immunology, Clinical Research or Studies, Endocrine System, Gene Transfer, Genomics, Growth Factors, Infectious Diseases or Agents, Inflammation, Inhibitors, Lymphocytes, Monoclonal Antibodies, Pathology, Pharmacology, Pharmacotherapy, Proteins and Macromolecules, Proteomics, Signal Transduction.

Additional Terms:

Cellular Immunology, Drug Development, Inhibitors, Pharmacotherapy, Phosphatidylinositol 3-Kinase, Protein Targeting and Sorting, Proteins and Macromolecules.

Profile Details

Last Updated: 9/5/2009

COS Expertise ID #686733
Reference this profile directly: http://myprofile.cos.com/jhayflick